

Review Article

The multifunctional role of phospho-calmodulin in pathophysiological processes

 **Antonio Villalobo**^{1,2}

¹Department of Cancer Biology, Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Arturo Duperier 4, E-28029 Madrid, Spain; ²Instituto de Investigaciones Sanitarias, Hospital Universitario La Paz, Edificio IdiPAZ, Paseo de la Castellana 261, E-28046 Madrid, Spain

Correspondence: Antonio Villalobo (antonio.villalobo@iib.uam.es; antonio.villalobo@idipaz.es)



Calmodulin (CaM) is a versatile Ca^{2+} -sensor/transducer protein that modulates hundreds of enzymes, channels, transport systems, transcription factors, adaptors and other structural proteins, controlling in this manner multiple cellular functions. In addition to its capacity to regulate target proteins in a Ca^{2+} -dependent and Ca^{2+} -independent manner, the posttranslational phosphorylation of CaM by diverse Ser/Thr- and Tyr-protein kinases has been recognized as an important additional manner to regulate this protein by fine-tuning its functionality. In this review, we shall cover developments done in recent years in which phospho-CaM has been implicated in signalling pathways that are relevant for the onset and progression of diverse pathophysiological processes. These include diverse systems playing a major role in carcinogenesis and tumour development, prion-induced encephalopathies and brain hypoxia, melatonin-regulated neuroendocrine disorders, hypertension, and heavy metal-induced cell toxicity.

Introduction

Calmodulin (CaM) is a ubiquitous highly conserved Ca^{2+} sensor/transducer protein in all eukaryotic cells. The Ca^{2+} -dependent and Ca^{2+} -independent functions of CaM are exerted by interacting and controlling the activity of hundreds of enzymes, channels, transport systems, and a variety of non-enzymatic proteins that are vital for the physiology of the cell [1–6]. As a Ca^{2+} sensor, CaM transduces the oscillations of the intracellular concentration of this cation during cell activation by growth factors, hormones, neuro-transmitters, and other effectors in meaningful cellular responses via CaM-dependent proteins. In addition, diverse posttranslational modifications of CaM have been recognized as a fine-tuning mechanism by which CaM-dependent proteins are also modulated [7]. This includes phosphorylation [8], trimethylation of Lys115 [9], acetylation of the N-terminal alanine residue [10], and carboxymethylation of aspartic and glutamic acids [11]. In this context, however, the phosphorylation of CaM takes a central functional stage.

Since the first report in 1983 by Plancke and Lazarides [12] describing the presence of Ser-phosphorylated CaM in chicken brain and skeletal muscle, and the *in vitro* phosphorylation of CaM by a preparation of phosphorylase b kinase, the biological importance of CaM phosphorylated at Ser/Thr and Tyr residues has been recognized. These phosphorylated CaM forms differentially regulate, when compared with non-phosphorylated CaM, a great variety of CaM-dependent systems [8]. The different residues phosphorylated by Ser/Thr- and Tyr-protein kinases are shown in Figure 1. It is important to remark the abundance of phosphorylatable residues located at the different EF-hands (Thr26, Thr29, Thr44, Tyr99, Tyr138, Ser101, Thr117) although not all are within the sequence of the Ca^{2+} -binding sites, and in the flexible central linker (Thr79, Ser81) connecting the N- and C-lobes of the protein. This underscores the importance that these phosphorylated residues may have in modifying the Ca^{2+} -binding capacity of CaM and/or its interaction with target proteins. In recent years, new progress has been done that helps to unravel the role of different phospho-CaM species in the control of important physiological processes and its implication in different pathologies. This short review

Received: 18 September 2018

Revised: 23 November 2018

Accepted: 30 November 2018

Version of Record published:
21 December 2018




Figure 1. NMR structure of apo-CaM showing the amino acid residues known to be phosphorylated by diverse protein kinases.

The figure depicts the NMR-derived structure of Ca²⁺-free CaM (apo-CaM) of *Xenopus laevis* showing the amino acid residues known to be phosphorylated by diverse Ser/Thr- and Tyr-protein kinases. Note the location of the phosphorylatable residues located at EF-hand I (Thr26 and Thr29), EF-hand III (Tyr99, Ser101) and EF-hand IV (Tyr138), and the flexible inter-lobe linker (Thr79 and Ser81). When phosphorylated, these residues may alter either the Ca²⁺-binding capacity of CaM or its interaction with target CaM-binding proteins. The structure was obtained from PDB ID: 1DMO [87].

covers the advances done since our previous one in 2002 [8], but centred on the functionality of phospho-Tyr-CaM and/or phospho-Ser/Thr-CaM in tumour cell biology, during neurological disorders, the dysfunction of the vascular system particularly its role in hypertension, dysregulations of the neuroendocrine melatonin system, and other cellular processes.

Phospho-Tyr-CaM in pathophysiology

Different phospho-Tyr-CaM species are implicated in signalling processes with pathophysiological implications. The kinases so far known to participate in CaM phosphorylation are the EGFR, the insulin receptor, and several non-receptor kinases such as c-Src and other Src family members, as well as Jak2 and p38Syk (see Table 1).

CaM regulates many signalling pathways and cellular functions relevant for the biology of cancerous cells [1]. It is expected, therefore, that different phospho-CaM species could be implicated in signalling routes leading to tumour cell transformation. In this section, we discuss some processes in which phospho-Tyr-CaM species are involved. There are several signalling systems very relevant for tumour cell proliferation and survival that are regulated by CaM, and where phospho-Tyr-CaM could play prominent regulatory roles. This includes the EGFR, the non-receptor tyrosine kinase c-Src, and the K-Ras/PI₃K/Akt pathway.

CaM has been shown to interact with the cytosolic juxtamembrane region of the EGFR in a Ca²⁺-dependent manner facilitating the ligand-dependent activation of the receptor in living cells [13–16]. As CaM is also a good substrate for the EGFR [17], it was expected that phospho-Tyr-CaM could also interact with the receptor. This indeed was the case [18,19], and the site of interaction of phospho-Tyr-CaM with the receptor was established to be the same that the one for non-phosphorylated CaM located at the cytosolic juxtamembrane region encompassing the sequence ⁶⁴⁵RRRHIVRKRTLRLQ⁶⁶⁰ [19]. The NMR-derived structure of a peptide corresponding to the transmembrane (TM) and the cytosolic juxtamembrane (JM_{cyt}) segment, where the CaM-BD is located, reconstituted in lipid bicelles shows that they form dimers and that the CaM-BD presents two helical segments divided by a flexible linker [20,21] (see Figure 2). This flexible linker is important to understand the expected bending of the JM_{cyt} to facilitate electrostatic interaction with the phosphoinositide-rich negatively charged inner leaflet of the plasma membrane to attain auto-inhibition of the EGFR in the absence of ligand

Table 1 Pathophysiological implication of phospho-Tyr- and phospho-Ser/Thr-CaM

Phospho-CaM species	Phosphorylated residue	Action on CaM	¹ Kinase	Exp. evidence	Biological effect (Ref.) Functional and pathological implications
p-Y-CaM	DGNGY ⁹⁹ ISAA	Affect EF-hand III	EGFR	<i>in vitro</i>	Phospho-Y-CaM enhances ligand-dependent EGFR activation [19]. Cancer
	GQVNY ¹³⁸ EEFV	Affect EF-hand IV	c-Src	<i>In vivo</i>	The pleiotrophin/PTPRZ1 pathway enhances CaM phosphorylation in SCLC [37]. Cancer
				<i>In silico</i> <i>In vitro</i>	Phospho-Y99-CaM binds to the SH2 domains of the regulatory p85 subunit of PI ₃ K activating its catalytic p110 subunit and the K-RasB/PI ₃ K/Akt pathway [32,33]. Enhances proliferation, cell survival, and resistance to apoptosis. Cancer
				<i>In vivo</i>	Hypoxia activates EGFR and c-Src enhancing phospho-Y99-CaM [41,44]. Brain hypoxia
			² SFKs	<i>In vitro</i>	Unknown effect of p-Y-CaM [8]. Leukaemia and lymphomas (?)
			Jak2	<i>In vivo</i>	Jak2/phospho-Tyr-CaM/NHE3 complex activates Na ⁺ reabsorption in kidney [48]. Hypertension
			INSR	<i>In vitro</i>	Unknown effect of p-Y-CaM [92]. Diabetes (?)
			p38Syk	<i>In vitro</i>	Unknown effect of p-Y-CaM [93].
p-S/T-CaM	DGDGT ²⁶ ITTK	Affect EF-hand I	CK2	<i>In vitro</i>	PrP increases the catalytic activity of CK2 inducing CaM phosphorylation [60]. Spongiform encephalopathy
	GTITT ²⁹ KELG	Affect EF-hand I		<i>In vitro</i>	Phospho-S ¹⁰¹ -CaM inhibits eNOS [62]. Decreased NO output result in lower vasodilation. Phospho-mimetic CaM(T79D) mutant decreases the Ca ²⁺ sensitivity of SK2 channel [65]. Phospho-T-CaM diminishes SK channel conductance [66]. Hypertension
	GQNPT ⁴⁴ EAEI	Affect EF-hand II		<i>In vivo</i>	Phospho-T ²⁹ -CaM enhances uranium binding [75,76]. Cell toxicity
	KMKDT ⁷⁹ DSEE	Affect flexible central linker			
	KDTS ⁸¹ EEEI	Affect flexible central linker		<i>In vitro</i>	Phospho-T ²⁹ -CaM enhances uranium binding [75,76]. Cell toxicity
	NGYIS ¹⁰¹ AAEL	Affect EF-hand III	CaMK-IV	<i>In vitro</i>	Phospho-T ⁴⁴ -CaM, phosphorylated by CaMK-IV, inhibits CaMK-II [68]
	GEKLT ¹¹⁷ DEEV	Affect EF-hand IV	PKC α	<i>In vitro</i> <i>In vivo</i>	Melatonin enhances phospho-S/T-CaM levels [72]. Sleep disorders
			MLCK	<i>In vitro</i>	Unknown effect of p-T-CaM [77]. Myopathies (?)
			PhK	<i>In vitro</i> <i>In vivo</i>	Unknown effect of p-S-CaM [12] Glucogen metabolopathies (?)

¹The kinases may phosphorylate one or more of the indicated residues.

²Includes other SFKs (v-Src, c-Fyn, c-Fgr).

CaM, calmodulin; CaMK-II/IV, CaM-dependent kinases II/IV; c-Src, cellular sarcoma kinase; EGFR, epidermal growth factor receptor; INSR, insulin receptor; Jak2, Janus kinase 2; MLCK, myosin light-chain kinase; NHE3, Na⁺/H⁺ exchanger 3; PhK, phosphorylase b kinase; PrP, prion protein; PTPRZ1, protein tyrosine-phosphatase receptor Z1; SCLC, small cells lung carcinoma; SFKs, Src-family kinases.

[22]. *In vitro* studies show that phospho-Tyr-CaM enhances the ligand-dependent activation of the EGFR, and this effect was observed as well using the phospho-mimetic CaM(Y99D/Y138D) mutant [19]. This suggests that phospho-Tyr-CaM could be an intracellular co-activator of the EGFR more efficient than non-phosphorylated CaM in detaching the CaM-binding domain of the inner leaflet of the plasma membrane to which is electrostatically bound [22], most provably due to the extra negative charges of phosphate. If this




Figure 2. NMR structure of the CaM-BD of the human EGFR reconstituted in lipid bicelles.

The figure depicts the NMR-derived dimeric structure of a TM-JM_{cyt} peptide of the EGFR reconstituted in lipid bicelles observed at different angles, and the interaction of phospho-Tyr99/Tyr138-CaM in the presence of Ca²⁺. The CaM-binding domain (CaM-BD), site of interaction of non-phosphorylated CaM and phospho-Tyr-CaM, in both TM-JM_{cyt} monomers is highlighted indicating the amino acid residues corresponding to the sequence ⁶⁴⁵RRRHIVRKRTLRLQLQ⁶⁶⁰. For clarity, the TM-JM_{cyt}, including the CaM-BD segments, of each monomer is indicated by numbers. The structures were obtained from PDB ID: 2M20 [20] (human EGFR TM-JM_{cyt}) and 1CLL (human CaM).

assumption is correct, we may expect that phospho-Tyr-CaM could play a relevant role in EGFR-signalling, particularly in tumours overexpressing this receptor.

The binding of CaM to c-Src was first demonstrated *in vitro* and several potential CaM-binding sites in this kinase identified [23,24]. The interaction of apo-CaM, and in lesser extent Ca²⁺/CaM, with c-Src induces a robust increase in its autophosphorylation and kinase activity towards exogenous substrates, as demonstrated *in vitro* and living cells [24,25]. In contrast with non-phosphorylated CaM, phospho-Tyr138-CaM does not co-immunoprecipitate with c-Src [18]. However, the phospho-mimetic mutants CaM (Y99D/Y138D) and CaM (Y99E/Y138E) strongly activate c-Src to the same level that non-phosphorylated CaM does, both in the absence and presence of Ca²⁺ [24]. One possibility is that phospho-Tyr99 could be required for the activation process. Nevertheless, it is not possible to infer from these experiments whether phospho-Tyr99-CaM and/or phospho-Tyr99/Tyr138-CaM interact with c-Src in living cells. This remains a possibility that deserves to be explored in the future. The identification of potential CaM-binding sites in the proximal [24] and terminal [23] regions of the SH2 domain of c-Src underscores the possibility that phospho-Tyr-CaM could interact with these sites.

In pancreatic tumour cells, it was shown that the interaction of CaM with the terminal region of the SH2 domain of c-Src facilitates its recruitment to the Fas death receptor signalling complex in a FADD-independent manner activating the c-Src/ERK pathway which promotes proliferation, cell survival, and resistant to apoptosis [23]. In this context, a series of compounds that disrupt the interaction of CaM with the SH2 domain of c-Src have been identified [26]. These compounds could be useful to prevent any potential action of CaM, and possibly phospho-Tyr-CaM, on c-Src signalling pathways. The possible action of phospho-Tyr-CaM on v-Src and other Src-family kinases relevant in diverse lymphoblastic tumours is an interesting topic pending to be

investigated, particularly since there is an intense cross-talk between the Ca^{2+} signal and many Src-family kinases [25,27].

The K-Ras/PI₃K/Akt pathway participates in cell proliferation and cell survival processes. K-RasB, but not H-Ras or N-Ras, binds to and is down-regulated by CaM [28]. Also, PI₃K is regulated by CaM upon binding to its 110 kDa catalytic subunit (p110) [29] and the 85 kDa regulatory subunit (p85) [30]. Phospho-Tyr99-CaM, probably produced by a Src-family kinase, also interacts with the two SH2 domains of the regulatory p85 subunit of PI₃K, activating in this manner its catalytic p110 subunit [31]. It has been shown that an extended form of phospho-Tyr99-CaM binds to the proximal SH2 domain (nSH2) of p85, while its distal SH2 domain (cSH2) interacts with a collapsed conformation of phospho-Tyr99-CaM which carries in addition K-Ras4B bound as determined *in vitro* by molecular simulation (see Figure 3). This tripartite interaction activates PI₃K, since K-Ras4B also allosterically acts on its catalytic subunit. The transformation of PIP₂ to PIP₃ in the cell membrane upon activation of PI₃K induces Akt binding to the membrane and activation, transmitting downstream proliferative signals that are relevant for K-Ras-driven tumours [32,33].

Using an engineered chicken B-lymphocyte tumour DT-40 cell line with the two functional CaM genes deleted, and one allele replaced by a CaM transgene repressible by tetracycline, it was shown that the expression of the non-phosphorylatable CaM mutants, CaM (Y99F), CaM (Y138F), or CaM (Y99F/Y138F) in the absence of endogenous wild-type CaM did not affect the growth and survival of the tumour cells. This suggests that phosphorylation of CaM at tyrosine residues was not required for the initiation and progression of these




Figure 3. Tripartite PI₃K/phospho-Tyr99-CaM/K-Ras4B complex.

The figure depicts a composite complex formed by phosphatidylinositol-4,5-bisphosphate-3-kinase (PI₃K) interacting with phospho-Tyr99-CaM (phospho-Tyr99-CaM) and K-Ras4B. To attain crystallization, the full-length p110α catalytic subunit (pink) was fused to a segment of the regulatory p85α subunit (blue) of PI₃K comprising the proximal SH2 domain (nSH2) and the inter-SH2 segment (iSH2) [88,89]. The distal SH2 domain (cSH2) is absent from the construct used for crystallization and it is shown as a dashed box. Phospho-Tyr99-CaM (brown) in an extended conformation interacts with the proximal SH2 domain (nSH2) of the regulatory p85α subunit of PI₃K (blue), while a collapsed conformation of phospho-Tyr99-CaM (brown), which is bound to K-Ras4B (green), interacts with its distal SH2 domain (cSH2) which is shown as a dashed box. K-Ras4B is represented in its GDP-bound conformation, and phospho-Tyr99 (-Tyr-P) CaM is highlighted. This theoretical model is based on reference [30], but it does not depict the actual interaction sites of the different proteins in the complex. The structures were obtained from PDB ID: 4L1B (human PI₃K, full-length p110α and 318–615 amino acid segment of p85α, at 2.6 Å X-ray resolution [88,89]), 1CLL and 1CFC (human and *Xenopus* CaM at 1.7 Å X-ray resolution and NMR-derived structure, respectively [87,90]) and 4LDJ (human K-Ras4B at 1.15 Å X-ray resolution [91]).

processes, although endogenous phospho-Tyr-CaM was detected in the conditional CaM-knockout cell line before CaM down-regulation [34]. It is important to mention that these tyrosine-defective mutants were previously characterized and were found to be biologically active [35].

Pleiotrophin is a ligand of the tyrosine-phosphatase receptor PTPRZ1 that upon binding to its extracellular domain induces dimerization. This phosphatase receptor is characterized by having two phosphatase sites, although the distal one is generally inactive. The distal phosphatase site of one PTPRZ1 monomer blocks the proximal active site of the apposed monomer, suppressing in this manner its activity [36]. As a consequence, pleiotrophin enhances the protein tyrosine phosphorylation level in the cell, and consequently it was shown that the pleiotrophin/PTPRZ1 pathway enhances CaM phosphorylation in SCLC cells [37]. Whether or not PTPRZ1-mediated tumour progression directly correlates with phospho-Tyr-CaM levels remains unknown.

Phospho-Tyr-CaM also participates in signalling processes relevant in the regulation of the vascular tone. In agreement with the stimulatory action of phospho-Tyr-CaM on nNOS, phospho-Tyr-CaM and the phospho-mimetic mutant CaM (Y99E/Y138E) also enhanced, albeit in minor degree, the catalytic activity of the eNOS isoform when assayed *in vitro*, when compared with wild-type non-phosphorylated CaM [38]. In contrast, phospho-Tyr-CaM and the phospho-mimetic mutant CaM (Y99D/Y138D) slightly inhibited bovine brain PDE1 when compared with wild-type non-phosphorylated CaM [38]. However, bovine heart PDE was inhibited *in vitro* by phospho-Tyr-CaM in a larger extent, as was reported earlier [39]. Moreover, the phospho-mimetic CaM(Y99E) mutant significantly inhibited eNOS *in vitro*, while no significant effect was found on the activity of nNOS or iNOS [40]. Overall, these observations suggest that the action of phospho-Tyr-CaM on NOS depends on the enzyme isoform, its tissular origin, and provably the phospho-Tyr residue of CaM involved. This underscores the existence of a great variety in regulatory mechanisms controlling CaM-dependent NO output implicated in vascular relaxation.

During experimental hypoxia of the brain, activation of the EGFR and c-Src [41,42] was observed. This leads to enhanced CaM phosphorylation at Tyr99 in the cerebral cortex and brain nuclei, particularly mediated by c-Src [43]. Phospho-Tyr99-CaM activates nNOS increasing the production of NO, and this potentially accelerates neuronal cell death. Puzzlingly, addition of an nNOS inhibitor before the onset of hypoxia prevents phospho-Tyr-CaM accumulation, suggesting that NO regulates EGFR and/or c-Src activation and hence the CaM phosphorylation process [41,44]. This is consistent with the biphasic regulation that NO exerts on EGFR activation [45,46].

Essential hypertension is a widespread heterogeneous illness in which a major pathophysiological factor is the inability of the kidney to excrete sodium at normal blood pressure. This results in altered fluid balance and increased arterial resistance that affect the correct function of many organs [47]. The Na⁺/H⁺-exchanger (NHE) plays a central role in Na⁺ reabsorption in the kidney proximal tubular system. It was demonstrated in cultured podocytes that NHE1 is regulated by CaM, which is Tyr-phosphorylated by Jak2, a process in which the EGFR also plays an important role [48]. In normal physiological conditions, Ang-II (angiotensin-II) activates this exchanger promoting Na⁺ retention and increasing the arterial blood pressure. Moreover, oxidative stress up-regulates the Ang-II receptor AT₁R, inducing enhanced Jak2-induced CaM phosphorylation and formation of the Jak2/phospho-Tyr-CaM/NHE3 complex, exacerbating Na⁺ retention leading to hypertension [49].

Phospho-Ser/Thr-CaM in pathophysiology

The best-studied Ser/Thr-kinase participating in CaM phosphorylation is CK2 (casein kinase 2), although other kinases, such as PhK, CaMK-IV, PKC α , and MLCK, also phosphorylate this protein. Phospho-Ser/Thr-CaM also participates in signalling pathways relevant in several diseases (see Table 1). In this section, some of these processes are discussed.

The ubiquitous kinase CK2 plays many functional roles phosphorylating a variety of protein substrates, and is implicated in cell viability and progression of the cell cycle [50]. The phosphorylation of CaM by CK2 occurs by the isolated catalytic α - and α' -subunits as demonstrated *in vitro*, while the N-terminal region of its regulatory β -subunit exerts an inhibitory effect [51,52]. CaM directly interacts with the β -subunit of CK2, and the C-terminal of CaM is implicated in the inhibitory effect of this subunit, as well as in the activation mediated by polybasic peptides [53]. It is expected, therefore, that the holoenzyme is unable to phosphorylate CaM. This was consistent with a report showing that the construct CK2 α_2^{1-335} β_2 does not phosphorylate CaM, although the CK2 α' -derived holoenzymes phosphorylated CaM when poly-Lys was present, while only weak phosphorylation was observed in its absence [54]. The absolute requirement of a basic polypeptide, including poly-Lys, for the phosphorylation of CaM by CK2 was earlier reported [55]. In fibroblasts, serum induces an

unbalanced overexpression of the CK2 α' -subunit without the corresponding expression of its β -subunit. It has been established that the former subunit acts as an oncogene, and in concert with H-Ras has transforming capacity. This is accompanied by increased cell proliferation rate and CaM phosphorylation in cultured cells due to the unabated excess of CK2 α' -subunit [56]. This suggests that phospho-CaM could play a role in the transformation process. Nevertheless, it cannot be excluded that other CK2 α' -subunit-substrates are also involved in the transformation process. Interestingly, the SH3 domain of the protein HS1 directly interacts with the CK2 α -subunit *in vitro* inhibiting CaM phosphorylation and expected H-Ras-mediated transformation [57]. This could open the possibility of using peptides derived from the SH3 domain of HS1 as potential therapeutics to inhibit tumour transformation.

Transmissible spongiform encephalopathies from animals and human are produced by infecting agents denoted prions. These agents are misfolded conformers of the host-coded glycoprotein PrP, which is able to interact and to induce non-reversible conformational changes in normal counterpart protein molecules generating the pathological accumulation of the so-called disease-associated protein PrP^d in the brain. This process produces neural vacuolation, astrocytosis, and neurodegeneration leading to serious neurological dysfunctions and patient death. Apparently, mutation of PrP can also favour or induce disease in the absence of an external infective agent [58,59]. CK2 is able to phosphorylate PrP at Ser154 *in vitro* [60], and conversely recombinant bovine PrP binds with high affinity to the catalytic α/α' -subunits of CK2. This interaction increases the catalytic activity of CK2 inducing CaM phosphorylation, and counteracts the inhibitory role that exerts its β -subunit [61]. As CK2 and CaM are both abundant in the brain, this opens the possibility that increased activity of this enzyme in spongiform encephalopathies and accumulation of phospho-CaM could play a role in the disease.

CK2 has been shown to phosphorylate several CaM residues, primarily affecting Thr79, Ser81, Ser101, and Thr117, although phosphorylation of Ser81 prevents subsequent phosphorylation of Thr79 [8,53]. CK2-phosphorylated CaM inhibits eNOS activity as mentioned earlier, and the phospho-Ser101 residue is likely to participate in the inhibition of eNOS [62]. The down-regulation of eNOS in endothelial cells by CK2-phosphorylated CaM could have profound consequences in NO output and hence its vasodilatory capacity leading to higher arterial blood pressure. It would be interesting to investigate whether this system is altered in hypertensive individuals.

CaM is constitutively bound to the C-terminal of the subunits forming homo-tetrameric small-conductance Ca^{2+} -activated K^+ (SK) channels [63] (see Figure 4), transducing in this manner the Ca^{2+} signal and opening the channel pore [64]. The CaM/SK channel also forms a multimeric complex with CK2 and PP2A reversibly regulating CaM phosphorylation levels. CK2 phosphorylates CaM only when the channel is closed [65]. Moreover, co-expression of SK2 channels with the phospho-mimetic CaM(T79D) mutant decreases the Ca^{2+} sensitivity of the channel, suggesting that phosphorylation of Thr79 by CK2 controls this process [65]. To clarify matters, in the latter work Thr79 was mislabelled as Thr80. This is the position corresponding to full-length CaM counting the N-terminal Met residue, which is not present in the mature protein. It has been shown that up-regulated CK2 in the hypothalamic paraventricular nucleus of spontaneously hypertensive rats increases the level of CaM phosphorylation, and phospho-CaM diminishes SK channel conductance altering the excitability of presympathetic neurons [66]. PIP_2 plays an important role mediating SK channels activation by CaM, as its binding site is located in the interphase of CaM/SK interaction. Moreover, phosphorylation of Thr79 by CK2 reduces the affinity for PIP_2 inducing greater inhibition of the channel [67]. These findings suggest that CK2-phosphorylated CaM, upon regulating SK channels, could intervene in the neural control of dysregulated vessels implicated in essential hypertension.

Brain hypoxia also activates CaMK-IV via c-Src, and the former activates the transcription factor CREB phosphorylating Ser133 enhancing the expression of pro-apoptotic proteins which initiate hypoxic neural cell death [42,43]. In contrast with the case of CaMK-II that poorly phosphorylates CaM, CaMK-IV is able to efficiently phosphorylate CaM at Thr44, which is located in the proximal region of the second EF-hand Ca^{2+} -binding site. Moreover, the authors of this report also demonstrated that CaM phosphorylated by CaMK-IV inhibits CaMK-II activity, when compared with non-phosphorylated CaM [68]. However, the action of phospho-Thr44-CaM on CaMK-IV itself was not reported.

Melatonin (5-methoxy-*N*-acetyltryptamine) is a neurohormone mainly synthesized and secreted by the pineal gland, also named epiphysis, located in the epithalamus between the two brain hemispheres, but extra pineal tissues also synthesize melatonin. This hormone controls the cyclic 24-h circadian rhythm, and plays many physiological functions in the organism, modulating, for example, the immune, neural, and cardiovascular systems, and exerting antioxidant actions among many other functions [69]. The melatonin receptor MT_2 is




Figure 4. Cryo-EM structure of the human SK4/CaM complex.

The figure depicts the cryo-electron microscope-derived structure at 4.7 Å resolution of the human SK4/CaM complex in the presence of Ca²⁺ (A). The four CaM molecules are highlighted in yellow (B). The four subunits of the SK4 channel (C) and the four CaM molecules indicating the phosphorylation of Thr79, Ser81, and Ser101 by casein kinase 2 in the central flexible linker and the third EF-hand Ca²⁺-binding site, respectively, (D) are shown in isolation in different colours. The structure was obtained from PDB ID: 6CNO [63].

a GPCR that is involved in many sleep and neuropsychiatric disorders, including insomnia, anxiety, and depression. Therefore, melatonin and other agonists of this receptor have been used to treat these disorders [70,71]. Melatonin has been shown to stimulate, at very low concentration, the phosphorylation of CaM mediated by PKCα in the presence of the phorbol ester PMA in an *in vitro* reconstituted system as well as in cultured cells [72]. In this process is implicated the downstream MAPK pathway, as determined using specific inhibitors blocking melatonin-induced CaM-phosphorylation. The authors of this work suggested that high serum melatonin levels during the dark phase of the circadian cycle may increase phospho-Ser/Thr-CaM concentration, down-regulating in this manner key CaM-dependent target enzymes sensitive to this phosphorylated modulator as previously described [8]. An intriguing possibility of interest to be studied in the future is the occurrence of alterations of melatonin-induced CaM-phosphorylation in sleep disorders and other neuropsychiatric illness.

Heavy metals are very toxic, and some of their actions are due to its interaction with CaM by altering its functionality [73,74]. Uranium chemical toxicity in living organisms is due, in part, to the interaction of the uranyl ion with cellular proteins. The first EF-hand Ca²⁺-binding motif of CaM has about thousand times more affinity for uranyl than for Ca²⁺, and *in vitro* studies demonstrated that phosphorylation of *Arabidopsis thaliana* CaM by CK2 at a threonine in the first Ca²⁺-binding loop, increases the uranyl affinity at physiological pH [75,76]. Another kinase known to phosphorylate the first EF-hand Ca²⁺-binding site of vertebrate CaM at Thr29, and in lesser extent Thr26, is MLCK [77]. It would be interesting to determine whether this kinase may

also contribute to this process. Uranium has an enormous toxic effect in cells of organisms contaminated with this radioactive element. This may be due, in part, to its disrupting effect on Ca^{2+} -binding to CaM preventing in this manner its normal functionality, in addition to the lasting noxious effects exerted by this radioactive element.

Perspectives

The diversity of phosphorylatable residues in CaM suggests that each one may have specific functionalities (see Figure 1 and Table 1). As examples to be investigated in the future, it would be relevant to establish whether phosphorylation of Thr79 and Ser81 in the flexible linker of CaM could play distinct or redundant roles in modifying its flexibility and therefore its capacity to rotate their N- and C-lobes, as this may be critical for its interaction with target proteins. A CaM deletion mutant lacking Thr79 and Asp80 induces the loss of a partial turn of the central α -helix resulting in the rotation of the C-lobe 220° with respect to the N-lobe positioning both lobes in a *cis* orientation, when compared with the *trans* orientation in wild-type CaM [78]. This was interpreted as to why this CaM mutant has decreased capacity to activate some CaM-binding enzymes, while has little or no effect on others. Although this is a very likely possibility when performing *in vitro* assays, it is not negligible to take in consideration that the absence of the phosphorylatable Thr79 residue in this mutant could be relevant when considering its lack of phosphorylation in living cells. To establish whether phospho-Tyr99 and phospho-Tyr138 play a distinct role in modifying the Ca^{2+} -binding capacity of CaM and/or to determine its interaction with target proteins containing SH2 and/or PTB domains are points of interest. Likewise, whether phosphorylation of both tyrosine residues in CaM is required or not to interact with some target proteins is also a relevant point.

Another topic deserving special attention is whether, in addition to the case of PI_3K , where the binding of phospho-Tyr-CaM to the two SH2 domains of its p85 regulatory subunit has been established [32], there are other proteins containing SH2 or PTB domains that may interact with phospho-Tyr-CaM regulating in this manner their activities as suggested earlier [8]. This includes the SH2 domain of c-Src, where potential CaM-binding sites have been identified [23,24]. This could be of particular importance, as this interaction may explain how phospho-Tyr-CaM differentially regulates diverse signalling pathways when compared with non-phosphorylated CaM. Furthermore, as CaM has the capacity to cluster different or identical subunits of a variety of CaM-binding proteins and to interact with separate segments of the same polypeptide chain [2], it is possible to visualize that phospho-Tyr-CaM could do the same, clustering two distinct SH2/PTB-containing proteins or protein subunits if each one simultaneously bind to the phospho-Tyr99 and the phospho-Tyr138 residues.

A series of natural occurring CaM mutants, impairing Ca^{2+} -binding, affect CaM-regulated ion channels in the heart causing some arrhythmias, including the bradycardic long QT syndrome and idiopathic ventricular fibrillation [79–84]. One possibility worth to be explored in the future is whether mutations affecting phosphorylatable CaM residues may also dysregulate ion channels in the heart and/or other organs. In this context, it has been shown in *Paramecium tetraurelia* that changing Ser101 by a non-phosphorylatable residue in CaM affects the ion channel-mediated motile response of the protozoa by acting on the low conductance Ca^{2+} -dependent K^+ channel [85]. As CK2 phosphorylates CaM at different residues, including Ser101, it is tempting to speculate whether the observed effect on this channel induced by the disabled CaM mutant could primarily be due to the absence of phospho-Ser101-CaM. This is supported by the fact that *Tetrahymena pyriformis* CaM, which has a phosphorylatable Thr instead of a Ser at position 101, restores the activity of dysfunctional Ca^{2+} -dependent K^+ channels [85]. Curiously, two additional mutations simultaneously occurring in the CaM (Ser101Phe) mutant that revert the phenotype are Asp80Tyr and Arg106Lys [86]. It would be interesting to investigate whether phosphorylation of Tyr80 by a Src-family kinase occurs in this mutant, and if positive, whether this phosphorylation is responsible for the suppressor activity of this triple mutant, as phospho-Tyr80 could mimic the effect of phospho-Ser101.

Abbreviations

Ang-II, angiotensin-II; AT₁R, Ang-II type 1 receptor; CaM, calmodulin; CaMK-II/IV, CaM-dependent kinases II/IV; CK2, casein kinase 2; CREB, cAMP response element-binding protein; c-Src, cellular sarcoma kinase; EGFR, epidermal growth factor receptor; EM, electron microscope; eNOS, endothelial nitric oxide synthase; ERK, extracellular-regulated kinase; FADD, Fas-associated protein with death domain; Fas, tumour-necrosis factor receptor superfamily member 6; GPCR, G protein-coupled receptor; HS1, hematopoietic lineage cell-specific

protein; iNOS, inducible nitric oxide synthase; Jak2, Janus kinase 2; MAPK, mitogen-activated protein kinase; MLCK, myosin light-chain kinase; NHE1/3, Na⁺/H⁺-exchangers 1/3; NMR, nuclear magnetic resonance; nNOS, neuronal nitric oxide synthase; PDB ID, protein data bank identification number; PDE1, 3',5'-cyclic nucleotide phosphodiesterase 1; PhK, phosphorylase b kinase; PI₃K, phosphatidylinositol-4,5-bisphosphate-3-kinase; PI₂, phosphatidylinositol 4,5-bisphosphate; PI₃, phosphatidylinositol 3,4,5-trisphosphate; PKC α , protein kinase C α ; PMA, 12-O-tetradecanoylphorbol-13-acetate; PP2A, protein phosphatase 2A; PrP, prion protein; PrP^d, disease-associated PrP; PTB, phospho-tyrosine binding; PTPRZ1, protein tyrosine-phosphatase receptor Z1; SCLC, small cells lung carcinoma; SH2, Src homology domain 2; SH3, Src homology domain 3; TM-JM_{cyt}, transmembrane-cytosolic juxtamembrane segment.

Funding

Original work in the author laboratory was funded by the *Secretaría de Estado de Investigación, Desarrollo e Innovación* [SAF2014-52048-R], and the *Consejería de Educación, Juventud y Deportes – Comunidad de Madrid* [B2017/BMD-36].

Competing Interests

The Author declares that there are no competing interests associated with this manuscript.

References

- Berchtold, M.W. and Villalobo, A. (2014) The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. *Biochim. Biophys. Acta, Mol. Cell Res.* **1843**, 398–435 <https://doi.org/10.1016/j.bbamcr.2013.10.021>
- Villalobo, A., Ishida, H., Vogel, H.J. and Berchtold, M.W. (2018) Calmodulin as a protein linker and a regulator of adaptor/scaffold proteins. *Biochim. Biophys. Acta, Mol. Cell Res.* **1865**, 507–521 <https://doi.org/10.1016/j.bbamcr.2017.12.004>
- Chin, D. and Means, A.R. (2000) Calmodulin: a prototypical calcium sensor. *Trends Cell Biol.* **10**, 322–328 [https://doi.org/10.1016/S0962-8924\(00\)01800-6](https://doi.org/10.1016/S0962-8924(00)01800-6)
- Jurado, L.A., Chockalingam, P.S. and Jarrett, H.W. (1999) Apocalmodulin. *Physiol. Rev.* **79**, 661–682 <https://doi.org/10.1152/physrev.1999.79.3.661>
- Hoeflich, K.P. and Ikura, M. (2002) Calmodulin in action: diversity in target recognition and activation mechanisms. *Cell* **108**, 739–742 [https://doi.org/10.1016/S0092-8674\(02\)00682-7](https://doi.org/10.1016/S0092-8674(02)00682-7)
- Klee, C.B. and Vanaman, T.C. (1982) Calmodulin. *Adv. Protein Chem.* **35**, 213–321 [https://doi.org/10.1016/S0065-3233\(08\)60470-2](https://doi.org/10.1016/S0065-3233(08)60470-2)
- Kortvely, E. and Gulya, K. (2004) Calmodulin, and various ways to regulate its activity. *Life Sci.* **74**, 1065–1070 <https://doi.org/10.1016/j.lfs.2003.07.026>
- Benaïm, G. and Villalobo, A. (2002) Phosphorylation of calmodulin. Functional implications. *Eur. J. Biochem.* **269**, 3619–3631 <https://doi.org/10.1046/j.1432-1033.2002.03038.x>
- Cobb, J.A. and Roberts, D.M. (2000) Structural requirements for N-trimethylation of lysine 115 of calmodulin. *J. Biol. Chem.* **275**, 18969–18975 <https://doi.org/10.1074/jbc.M002332200>
- Watterson, D.M., Sharief, F. and Vanaman, T.C. (1980) The complete amino acid sequence of the Ca²⁺-dependent modulator protein (calmodulin) of bovine brain. *J. Biol. Chem.* **255**, 962–975 PMID:7356670
- Billingsley, M.L., Velletri, P.A., Roth, R.H. and DeLorenzo, R.J. (1983) Carboxymethylation of calmodulin inhibits calmodulin-dependent phosphorylation in rat brain membranes and cytosol. *J. Biol. Chem.* **258**, 5352–5357 PMID:6853519
- Plancke, Y.D. and Lazarides, E. (1983) Evidence for a phosphorylated form of calmodulin in chicken brain and muscle. *Mol. Cell. Biol.* **3**, 1412–1420 <https://doi.org/10.1128/MCB.3.8.1412>
- Martin-Nieto, J. and Villalobo, A. (1998) The human epidermal growth factor receptor contains a juxtamembrane calmodulin-binding site. *Biochemistry* **37**, 227–236 <https://doi.org/10.1021/bi971765v>
- Li, H., Panina, S., Kaur, A., Ruano, M.J., Sanchez-Gonzalez, P., la Cour, J.M. et al. (2012) Regulation of the ligand-dependent activation of the epidermal growth factor receptor by calmodulin. *J. Biol. Chem.* **287**, 3273–3281 <https://doi.org/10.1074/jbc.M111.317529>
- Martin-Nieto, J., Cusidó-Hita, D.M., Li, H., Benguría, A. and Villalobo, A. (2002) Regulation of ErbB receptors by calmodulin. *Recent Res. Develop. Biochem.* **3**, 41–58
- Sánchez-González, P., Jellali, K. and Villalobo, A. (2010) Calmodulin-mediated regulation of the epidermal growth factor receptor. *FEBS J.* **277**, 327–342 <https://doi.org/10.1111/j.1742-4658.2009.07469.x>
- Benguría, A., Hernández-Perera, O., Martínez-Pastor, M.T., Sacks, D.B. and Villalobo, A. (1994) Phosphorylation of calmodulin by the epidermal-growth-factor-receptor tyrosine kinase. *Eur. J. Biochem.* **224**, 909–916 <https://doi.org/10.1111/j.1432-1033.1994.00909.x>
- Wu, J., Masci, P.P., Chen, C., Chen, J., Lavin, M.F. and Zhao, K.N. (2015) β -Adducin siRNA disruption of the spectrin-based cytoskeleton in differentiating keratinocytes prevented by calcium acting through calmodulin/epidermal growth factor receptor/cadherin pathway. *Cell Signal.* **27**, 15–25 <https://doi.org/10.1016/j.cellsig.2014.10.001>
- Stateva, S.R., Salas, V., Benguría, A., Cossio, I., Anguita, E., Martin-Nieto, J. et al. (2015) The activating role of phospho-(Tyr)-calmodulin on the epidermal growth factor receptor. *Biochem. J.* **472**, 195–204 <https://doi.org/10.1042/BJ20150851>
- Endres, N.F., Das, R., Smith, A.W., Arkhipov, A., Kovacs, E., Huang, Y. et al. (2013) Conformational coupling across the plasma membrane in activation of the EGF receptor. *Cell* **152**, 543–556 <https://doi.org/10.1016/j.cell.2012.12.032>
- Sinclair, J.K.L., Walker, A.S., Doerner, A.E. and Schepartz, A. (2018) Mechanism of allosteric coupling into and through the plasma membrane by EGFR. *Cell Chem. Biol.* **25**, 857–870.e857 <https://doi.org/10.1016/j.chembiol.2018.04.005>

- 22 McLaughlin, S., Smith, S.O., Hayman, M.J. and Murray, D. (2005) An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family. *J. Gen. Physiol.* **126**, 41–53 <https://doi.org/10.1085/jgp.200509274>
- 23 Yuan, K., Jing, G., Chen, J., Liu, H., Zhang, K., Li, Y. et al. (2011) Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). *J. Biol. Chem.* **286**, 24776–24784 <https://doi.org/10.1074/jbc.M110.202804>
- 24 Stateva, S.R., Salas, V., Anguita, E., Benaim, G. and Villalobo, A. (2015) Ca²⁺/calmodulin and apo-calmodulin both bind to and enhance the tyrosine kinase activity of c-Src. *PLoS ONE* **10**, e0128783 <https://doi.org/10.1371/journal.pone.0128783>
- 25 Anguita, E. and Villalobo, A. (2017) Src-family tyrosine kinases and the Ca²⁺ signal. *Biochim. Biophys. Acta, Mol. Cell Res.* **1864**, 915–932 <https://doi.org/10.1016/j.bbamcr.2016.10.022>
- 26 Tzou, Y.M., Bailey, S.K., Yuan, K., Shin, R., Zhang, W., Chen, Y. et al. (2016) Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer. *Bioorg. Med. Chem. Lett.* **26**, 1237–1244 <https://doi.org/10.1016/j.bmcl.2016.01.027>
- 27 Anguita, E. and Villalobo, A. (2018) Ca²⁺ signaling and Src-kinases-controlled cellular functions. *Arch. Biochem. Biophys.* **650**, 59–74 <https://doi.org/10.1016/j.abb.2018.05.005>
- 28 Villalonga, P., Lopez-Alcala, C., Bosch, M., Chiloeches, A., Rocamora, N., Gil, J. et al. (2001) Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. *Mol. Cell. Biol.* **21**, 7345–7354 <https://doi.org/10.1128/MCB.21.21.7345-7354.2001>
- 29 Fischer, R., Julsgart, J. and Berchtold, M.W. (1998) High affinity calmodulin target sequence in the signalling molecule PI 3-kinase. *FEBS Lett.* **425**, 175–177 [https://doi.org/10.1016/S0014-5793\(98\)00225-7](https://doi.org/10.1016/S0014-5793(98)00225-7)
- 30 Wang, G., Zhang, M., Jang, H., Lu, S., Lin, S., Chen, G. et al. (2018) Interaction of calmodulin with the cSH2 domain of the p85 regulatory subunit. *Biochemistry* **57**, 1917–1928 <https://doi.org/10.1021/acs.biochem.7b01130>
- 31 Chaudhuri, P., Rosenbaum, M.A., Sinharoy, P., Damron, D.S., Birnbaumer, L. and Graham, L.M. (2016) Membrane translocation of TRPC6 channels and endothelial migration are regulated by calmodulin and PI3 kinase activation. *Proc. Natl Acad. Sci. U.S.A.* **113**, 2110–2115 <https://doi.org/10.1073/pnas.1600371113>
- 32 Zhang, M., Jang, H., Gaponenko, V. and Nussinov, R. (2017) Phosphorylated calmodulin promotes PI3K activation by binding to the SH2 domains. *Biophys. J.* **113**, 1956–1967 <https://doi.org/10.1016/j.bpj.2017.09.008>
- 33 Nussinov, R., Wang, G., Tsai, C.J., Jang, H., Lu, S., Banerjee, A. et al. (2017) Calmodulin and PI3K signaling in KRAS cancers. *Trends Cancer* **3**, 214–224 <https://doi.org/10.1016/j.trecan.2017.01.007>
- 34 Panina, S., Stephan, A., la Cour, J.M., Jacobsen, K., Kallerup, L.K., Bumbuleviciute, R. et al. (2012) Significance of calcium binding, tyrosine phosphorylation, and lysine trimethylation for the essential function of calmodulin in vertebrate cells analyzed in a novel gene replacement system. *J. Biol. Chem.* **287**, 18173–18181 <https://doi.org/10.1074/jbc.M112.339382>
- 35 Salas, V., Sanchez-Torres, J., Cusido-Hita, D.M., Garcia-Marchan, Y., Sojo, F., Benaim, G. et al. (2005) Characterisation of tyrosine-phosphorylation-defective calmodulin mutants. *Protein Expr. Purif.* **41**, 384–392 <https://doi.org/10.1016/j.pep.2005.01.004>
- 36 Blanchetot, C., Tertoolen, L.G., Overvoorde, J. and den Hertog, J. (2002) Intra- and intermolecular interactions between intracellular domains of receptor protein-tyrosine phosphatases. *J. Biol. Chem.* **277**, 47263–47269 <https://doi.org/10.1074/jbc.M205810200>
- 37 Makinoshima, H., Ishii, G., Kojima, M., Fujii, S., Higuchi, Y., Kuwata, T. et al. (2012) PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma. *BMC Cancer* **12**, 537 <https://doi.org/10.1186/1471-2407-12-537>
- 38 Stateva, S.R., Salas, V., Benaim, G., Menéndez, M., Solis, D. and Villalobo, A. (2015) Characterization of phospho-(tyrosine)-mimetic calmodulin mutants. *PLoS ONE* **10**, e0120798 <https://doi.org/10.1371/journal.pone.0120798>
- 39 Palomo-Jiménez, P.I., Hernández-Hernando, S., García-Nieto, R.M. and Villalobo, A. (1999) A method for the purification of phospho(Tyr)calmodulin free of nonphosphorylated calmodulin. *Protein Expr. Purif.* **16**, 388–395 <https://doi.org/10.1006/prep.1999.1092>
- 40 Piazza, M., Futrega, K., Spratt, D.E., Dieckmann, T. and Guillemette, J.G. (2012) Structure and dynamics of calmodulin (CaM) bound to nitric oxide synthase peptides: effects of a phosphomimetic CaM mutation. *Biochemistry* **51**, 3651–3661 <https://doi.org/10.1021/bi300327z>
- 41 Mishra, O.P., Ashraf, Q.M. and Delivoria-Papadopoulos, M. (2010) Hypoxia-induced activation of epidermal growth factor receptor (EGFR) kinase in the cerebral cortex of newborn piglets: the role of nitric oxide. *Neurochem. Res.* **35**, 1471–1477 <https://doi.org/10.1007/s11064-010-0208-1>
- 42 Delivoria-Papadopoulos, M., Ashraf, Q.M. and Mishra, O.P. (2011) Mechanism of CaM kinase IV activation during hypoxia in neuronal nuclei of the cerebral cortex of newborn piglets: the role of Src kinase. *Neurochem. Res.* **36**, 1512–1519 <https://doi.org/10.1007/s11064-011-0477-3>
- 43 Delivoria-Papadopoulos, M., Ashraf, Q.M. and Mishra, O.P. (2011) Brain tissue energy dependence of CaM kinase IV cascade activation during hypoxia in the cerebral cortex of newborn piglets. *Neurosci. Lett.* **491**, 113–117 <https://doi.org/10.1016/j.neulet.2011.01.017>
- 44 Mishra, O.P., Ashraf, Q.M. and Delivoria-Papadopoulos, M. (2010) Mechanism of increased tyrosine (Tyr⁹⁹) phosphorylation of calmodulin during hypoxia in the cerebral cortex of newborn piglets: the role of nNOS-derived nitric oxide. *Neurochem. Res.* **35**, 67–75 <https://doi.org/10.1007/s11064-009-0031-8>
- 45 Villalobo, A. (2006) Nitric oxide and cell proliferation. *FEBS J.* **273**, 2329–2344 <https://doi.org/10.1111/j.1742-4658.2006.05250.x>
- 46 Villalobo, A. (2007) Enhanced cell proliferation induced by nitric oxide. *Dynamic Cell Biol.* **1**, 60–64
- 47 Staessen, J.A., Wang, J., Bianchi, G. and Birkenhager, W.H. (2003) Essential hypertension. *Lancet* **361**, 1629–1641 [https://doi.org/10.1016/S0140-6736\(03\)13302-8](https://doi.org/10.1016/S0140-6736(03)13302-8)
- 48 Coaxum, S.D., Garnovskaya, M.N., Gooz, M., Baldys, A. and Raymond, J.R. (2009) Epidermal growth factor activates Na⁺/H⁺ exchanger in podocytes through a mechanism that involves Janus kinase and calmodulin. *Biochim. Biophys. Acta, Mol. Cell Res.* **1793**, 1174–1181 <https://doi.org/10.1016/j.bbamcr.2009.03.006>
- 49 Banday, A.A. and Lokhandwala, M.F. (2011) Oxidative stress causes renal angiotensin II type 1 receptor upregulation, Na⁺/H⁺ exchanger 3 overstimulation, and hypertension. *Hypertension* **57**, 452–459 <https://doi.org/10.1161/HYPERTENSIONAHA.110.162339>
- 50 Litchfield, D.W. (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. *Biochem. J.* **369**, 1–15 <https://doi.org/10.1042/bj20021469>
- 51 Cosmelli, D., Antonelli, M., Allende, C.C. and Allende, J.E. (1997) An inactive mutant of the alpha subunit of protein kinase CK2 that traps the regulatory CK2beta subunit. *FEBS Lett.* **410**, 391–396 [https://doi.org/10.1016/S0014-5793\(97\)00625-X](https://doi.org/10.1016/S0014-5793(97)00625-X)

- 52 Marin, O., Meggio, F., Sarno, S. and Pinna, L.A. (1997) Physical dissection of the structural elements responsible for regulatory properties and intersubunit interactions of protein kinase CK2 beta-subunit. *Biochemistry* **36**, 7192–7198 <https://doi.org/10.1021/bi962885q>
- 53 Arrigoni, G., Marin, O., Pagano, M.A., Settimo, L., Paolin, B., Meggio, F. et al. (2004) Phosphorylation of calmodulin fragments by protein kinase CK2. Mechanistic aspects and structural consequences. *Biochemistry* **43**, 12788–12798 <https://doi.org/10.1021/bi049365c>
- 54 Olsen, B.B., Rasmussen, T., Niefind, K. and Issinger, O.G. (2008) Biochemical characterization of CK2 α and α' paralogues and their derived holoenzymes: evidence for the existence of a heterotrimeric CK2 α' -holoenzyme forming trimeric complexes. *Mol. Cell Biochem.* **316**, 37–47 <https://doi.org/10.1007/s11010-008-9824-3>
- 55 Meggio, F., Boldyreff, B., Issinger, O.G. and Pinna, L.A. (1994) Casein kinase 2 down-regulation and activation by polybasic peptides are mediated by acidic residues in the 55–64 region of the beta-subunit. A study with calmodulin as phosphorylatable substrate. *Biochemistry* **33**, 4336–4342 <https://doi.org/10.1021/bi00180a030>
- 56 Orlandini, M., Semplici, F., Ferruzzi, R., Meggio, F., Pinna, L.A. and Oliviero, S. (1998) Protein kinase CK2 α' is induced by serum as a delayed early gene and cooperates with Ha-*ras* in fibroblast transformation. *J. Biol. Chem.* **273**, 21291–21297 <https://doi.org/10.1074/jbc.273.33.21291>
- 57 Ruzzene, M., Brunati, A.M., Sarno, S., Donella-Deana, A. and Pinna, L.A. (1999) Hematopoietic lineage cell specific protein 1 associates with and down-regulates protein kinase CK2. *FEBS Lett.* **461**, 32–36 [https://doi.org/10.1016/S0014-5793\(99\)01409-X](https://doi.org/10.1016/S0014-5793(99)01409-X)
- 58 Jeffrey, M. and Gonzalez, L. (2007) Classical sheep transmissible spongiform encephalopathies: pathogenesis, pathological phenotypes and clinical disease. *Neuropathol. Appl. Neurobiol.* **33**, 373–394 <https://doi.org/10.1111/j.1365-2990.2007.00868.x>
- 59 Cancellotti, E., Barron, R.M., Bishop, M.T., Hart, P., Wiseman, F. and Manson, J.C. (2007) The role of host PrP in transmissible spongiform encephalopathies. *Biochim. Biophys. Acta, Mol. Basis Dis.* **1772**, 673–680 <https://doi.org/10.1016/j.bbdis.2006.10.013>
- 60 Negro, A., Meggio, F., Bertoli, A., Battistutta, R., Sorgato, M.C. and Pinna, L.A. (2000) Susceptibility of the prion protein to enzymic phosphorylation. *Biochem. Biophys. Res. Commun.* **271**, 337–341 <https://doi.org/10.1006/bbrc.2000.2628>
- 61 Meggio, F., Negro, A., Sarno, S., Ruzzene, M., Bertoli, A., Sorgato, M.C. et al. (2000) Bovine prion protein as a modulator of protein kinase CK2. *Biochem. J.* **352**, 191–196 <https://doi.org/10.1042/bj3520191>
- 62 Greif, D.M., Sacks, D.B. and Michel, T. (2004) Calmodulin phosphorylation and modulation of endothelial nitric oxide synthase catalysis. *Proc. Natl Acad. Sci. U.S.A.* **101**, 1165–1170 <https://doi.org/10.1073/pnas.0306377101>
- 63 Lee, C.H. and MacKinnon, R. (2018) Activation mechanism of a human SK-calmodulin channel complex elucidated by cryo-EM structures. *Science* **360**, 508–513 <https://doi.org/10.1126/science.aas9466>
- 64 Adelman, J.P., Maylie, J. and Sah, P. (2012) Small-conductance Ca²⁺-activated K⁺ channels: form and function. *Annu. Rev. Physiol.* **74**, 245–269 <https://doi.org/10.1146/annurev-physiol-020911-153336>
- 65 Allen, D., Fakler, B., Maylie, J. and Adelman, J.P. (2007) Organization and regulation of small conductance Ca²⁺-activated K⁺ channel multiprotein complexes. *J. Neurosci.* **27**, 2369–2376 <https://doi.org/10.1523/JNEUROSCI.3565-06.2007>
- 66 Pachau, J., Li, D.P., Chen, S.R., Lee, H.A. and Pan, H.L. (2014) Protein kinase CK2 contributes to diminished small conductance Ca²⁺-activated K⁺ channel activity of hypothalamic pre-sympathetic neurons in hypertension. *J. Neurochem.* **130**, 657–667 <https://doi.org/10.1111/jnc.12758>
- 67 Zhang, M., Meng, X.Y., Cui, M., Pascal, J.M., Logothetis, D.E. and Zhang, J.F. (2014) Selective phosphorylation modulates the PIP2 sensitivity of the CaM-SK channel complex. *Nat. Chem. Biol.* **10**, 753–759 <https://doi.org/10.1038/nchembio.1592>
- 68 Ishida, A., Kameshita, I., Okuno, S., Kitani, T. and Fujisawa, H. (2002) Phosphorylation of calmodulin by Ca²⁺/calmodulin-dependent protein kinase IV. *Arch. Biochem. Biophys.* **407**, 72–82 [https://doi.org/10.1016/S0003-9861\(02\)00514-3](https://doi.org/10.1016/S0003-9861(02)00514-3)
- 69 Tordjman, S., Chokron, S., Delorme, R., Charrier, A., Bellissant, E., Jaafari, N. et al. (2017) Melatonin: pharmacology, functions and therapeutic benefits. *Curr. Neuropharmacol.* **15**, 434–443 <https://doi.org/10.2174/1570159X14666161228122115>
- 70 Comai, S. and Gobbi, G. (2014) Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. *J. Psychiatry Neurosci.* **39**, 6–21 <https://doi.org/10.1503/jpn.130009>
- 71 McGrane, I.R., Leung, J.G., St Louis, E.K. and Boeve, B.F. (2015) Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. *Sleep Med.* **16**, 19–26 <https://doi.org/10.1016/j.sleep.2014.09.011>
- 72 Soto-Vega, E., Meza, I., Ramirez-Rodriguez, G. and Benitez-King, G. (2004) Melatonin stimulates calmodulin phosphorylation by protein kinase C. *J. Pineal Res.* **37**, 98–106 <https://doi.org/10.1111/j.1600-079X.2004.00141.x>
- 73 Cox, J.L. and Harrison, Jr, S.D. (1983) Correlation of metal toxicity with in vitro calmodulin inhibition. *Biochem. Biophys. Res. Commun.* **115**, 106–111 [https://doi.org/10.1016/0006-291X\(83\)90975-0](https://doi.org/10.1016/0006-291X(83)90975-0)
- 74 Vig, P.J., Nath, R. and Desaiah, D. (1989) Metal inhibition of calmodulin activity in monkey brain. *J. Appl. Toxicol.* **9**, 313–316 <https://doi.org/10.1002/jat.2550090506>
- 75 Sauge-Merle, S., Brulfert, F., Pardoux, R., Solari, P.L., Lemaire, D., Safi, S. et al. (2017) Structural analysis of uranyl complexation by the EF-hand motif of calmodulin: effect of phosphorylation. *Chemistry* **23**, 15505–15517 <https://doi.org/10.1002/chem.201703484>
- 76 Pardoux, R., Sauge-Merle, S., Lemaire, D., Delangle, P., Guillemau, L., Adriano, J.M. et al. (2012) Modulating uranium binding affinity in engineered calmodulin EF-hand peptides: effect of phosphorylation. *PLoS ONE* **7**, e41922 <https://doi.org/10.1371/journal.pone.0041922>
- 77 Davis, H.W., Crimmins, D.L., Thoma, R.S. and Garcia, J.G. (1996) Phosphorylation of calmodulin in the first calcium-binding pocket by myosin light chain kinase. *Arch. Biochem. Biophys.* **332**, 101–109 <https://doi.org/10.1006/abbi.1996.0321>
- 78 Tabernero, L., Taylor, D.A., Chandross, R.J., VanBerkum, M.F., Means, A.R., Quiocho, F.A. et al. (1997) The structure of a calmodulin mutant with a deletion in the central helix: implications for molecular recognition and protein binding. *Structure* **5**, 613–622 [https://doi.org/10.1016/S0969-2126\(97\)00217-7](https://doi.org/10.1016/S0969-2126(97)00217-7)
- 79 Shaik, N.A., Awan, Z.A., Verma, P.K., Elango, R. and Banaganapalli, B. (2018) Protein phenotype diagnosis of autosomal dominant calmodulin mutations causing irregular heart rhythms. *J. Cell. Biochem.* **119**, 8233–8248 <https://doi.org/10.1002/jcb.26834>
- 80 Crotti, L., Johnson, C.N., Graf, E., De Ferrari, G.M., Cuneo, B.F., Ovidia, M. et al. (2013) Calmodulin mutations associated with recurrent cardiac arrest in infants. *Circulation* **127**, 1009–1017 <https://doi.org/10.1161/CIRCULATIONAHA.112.001216>
- 81 Yin, G., Hassan, F., Haroun, A.R., Murphy, L.L., Crotti, L., Schwartz, P.J. et al. (2014) Arrhythmogenic calmodulin mutations disrupt intracellular cardiomyocyte Ca²⁺ regulation by distinct mechanisms. *J. Am. Heart Assoc.* **3**, e000996 <https://doi.org/10.1161/JAHA.114.000996>

- 82 Pipilas, D.C., Johnson, C.N., Webster, G., Schlaepfer, J., Fellmann, F., Sekarski, N. et al. (2016) Novel calmodulin mutations associated with congenital long QT syndrome affect calcium current in human cardiomyocytes. *Heart Rhythm*. **13**, 2012–2019 <https://doi.org/10.1016/j.hrthm.2016.06.038>
- 83 Berchtold, M.W., Zacharias, T., Kulej, K., Wang, K., Torggler, R., Jespersen, T. et al. (2016) The arrhythmogenic calmodulin mutation D129G dysregulates cell growth, calmodulin-dependent kinase II activity, and cardiac function in zebrafish. *J. Biol. Chem.* **291**, 26636–26646 <https://doi.org/10.1074/jbc.M116.758680>
- 84 Rocchetti, M., Sala, L., Dreizehnter, L., Crotti, L., Sinnecker, D., Mura, M. et al. (2017) Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. *Cardiovasc. Res.* **113**, 531–541 <https://doi.org/10.1093/cvr/cvx006>
- 85 Hinrichsen, R., Wilson, E., Lukas, T., Craig, T., Schultz, J. and Watterson, D.M. (1990) Analysis of the molecular basis of calmodulin defects that affect ion channel-mediated cellular responses: site-specific mutagenesis and microinjection. *J. Cell. Biol.* **111**, 2537–2542 <https://doi.org/10.1083/jcb.111.6.2537>
- 86 Hinrichsen, R.D., Pollock, M., Hennessey, T. and Russell, C. (1991) An intragenic suppressor of a calmodulin mutation in *Paramecium*: genetic and biochemical characterization. *Genetics* **129**, 717–725 PMID:1661255
- 87 Zhang, M., Tanaka, T. and Ikura, M. (1995) Calcium-induced conformational transition revealed by the solution structure of apo calmodulin. *Nat. Struct. Biol.* **2**, 758–767 <https://doi.org/10.1038/nsb0995-758>
- 88 Huang, C.H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V.E., Kinzler, K.W. et al. (2007) The structure of a human p110 α /p85 α complex elucidates the effects of oncogenic PI3K α mutations. *Science* **318**, 1744–1748 <https://doi.org/10.1126/science.1150799>
- 89 Zhao, Y., Zhang, X., Chen, Y., Lu, S., Peng, Y., Wang, X. et al. (2014) Crystal structures of PI3K α complexed with PI103 and its derivatives: new directions for inhibitors design. *ACS Med. Chem. Lett.* **5**, 138–142 <https://doi.org/10.1021/ml400378e>
- 90 Chattopadhyaya, R., Meador, W.E., Means, A.R. and Quijcho, F.A. (1992) Calmodulin structure refined at 1.7 Å resolution. *J. Mol. Biol.* **228**, 1177–1192 [https://doi.org/10.1016/0022-2836\(92\)90324-D](https://doi.org/10.1016/0022-2836(92)90324-D)
- 91 Sogabe, S., Kamada, Y., Miwa, M., Niida, A., Sameshima, T., Kamaura, M. et al. (2017) Crystal structure of a human K-Ras G12D mutant in complex with GDP and the cyclic inhibitory peptide KRpep-2d. *ACS Med. Chem. Lett.* **8**, 732–736 <https://doi.org/10.1021/acsmedchemlett.7b00128>
- 92 Williams, J.P., Jo, H., Sacks, D.B., Crimmins, D.L., Thoma, R.S., Hunnicutt, R.E. et al. (1994) Tyrosine-phosphorylated calmodulin has reduced biological activity. *Arch. Biochem. Biophys.* **315**, 119–126 <https://doi.org/10.1006/abbi.1994.1479>
- 93 Meggio, F., Brunati, A.M. and Pinna, L.A. (1987) Polyclonal-dependent, Ca²⁺-antagonized phosphorylation of calmodulin by casein kinase-2 and a spleen tyrosine protein kinase. *FEBS Lett.* **215**, 241–246 [https://doi.org/10.1016/0014-5793\(87\)80154-0](https://doi.org/10.1016/0014-5793(87)80154-0)